Cysteinyl leukotrienes in asthma: current state of therapeutic evaluation

Ian K Taylor

Among the many inflammatory mediators implicated in asthma, the cysteinyl leukotrienes (LTC₄, LTD₄ and LTE₄) – peptidolipid conjugates formed following lipooxygenation of arachidonic acid – have attracted much attention.¹-⁶ They are generated in vitro following immunological and non-immunological challenge from lung tissue¹ and purified mast cells,⁸ monocytes/macrophages,⁷ and eosinophils.⁸ The biological actions of the cysteinyl leukotrienes have now been extensively characterised; within the lung they can impair mucociliary clearance, enhance mucus secretion, and facilitate changes in pulmonary vascular permeability.¹⁻⁶ Their potent spasmogenic properties on human airway smooth muscle both in vitro and in vivo have similarly been comprehensively documented¹⁰⁻¹⁴ and further evidence suggests that they increase bronchial hyperresponsiveness.¹⁵⁻¹⁸ These properties, which reproduce some of the functional and histological features of clinical asthma, have generated considerable interest in the quantification in vivo of cysteinyl leukotrienes in asthmatic subjects. In addition, the development and emergence of potent end organ receptor antagonists and synthesis inhibitors have enabled an insight into the role of these mediators in asthma.

Whilst a role for leukotrienes has been suggested in a wide variety of other diseases including hepatoportal syndromes, myocardial ischaemia, and inflammatory conditions of the bowel, skin and joints,³ this article reviews the evidence of their involvement principally in asthma and, to a lesser extent, allergic rhinitis. Only clinical studies in asthmatic patients will be considered, to the exclusion of animal and in vitro data, and will comprise three parts: (1) a review of those studies in which cysteinyl leukotriene generation in vivo has been demonstrated either (a) following administration to the airway of indirect bronchoconstrictor challenges, (b) during clinical disease exacerbations, or (c) under basal conditions; (2) those studies in which there have been attempts pharmacologically to modulate cysteinyl leukotriene generation or to attenuate their end organ effects in the airway under (a) unprovoked conditions, (b) following bronchoprovocative stimuli, or (c) in chronic persistent asthma; and (3) most importantly, given the current available evidence, a critical evaluation of the therapeutic potential of these drugs in human asthma.

Evidence for cysteinyl leukotriene release in asthma

It is axiomatic that the most suitable place to measure inflammatory mediators is at their putative site of action. The nose is readily accessible to evaluate mediator production and cysteinyl leukotrienes have been quantified in nasal secretions following local allergen challenge.¹⁹⁻²⁰ The use of the fibreoptic bronchoscope coupled with bronchoalveolar lavage (BAL) now permits similar studies in the lower respiratory tract and abundant evidence exists on cellular profiles, cellular activation status, and secretory products within the asthmatic airway. Whilst initial reservations over the safety and tolerability of such procedures were expressed, there is now general acceptance of their use in asthmatic subjects with a wide spectrum of disease severity,²¹ although doubts remain over interpretation of BAL solute data.²² Notwithstanding these reservations, increased quantities of cysteinyl leukotrienes have been recovered from BAL fluid both in patients with chronic persistent asthma²³⁻²⁴ and following bronchoprovocation.²⁵⁻²⁶ Plasma sampling and interpretation of data are less problematic, but plasma concentrations of proinflammatory mediators are, in many cases, exceedingly low, making detection and quantification difficult. Furthermore, invasive sampling may result in ex vivo generation of mediators secondary to activation and repeated measurements are required to give a time integrated insight of their production.

Biochemical analysis of urine, however, circumvents many of these problems. In the absence of renal synthesis, urinary mediator (or metabolite) levels will reflect plasma levels. Urine collections are easy to perform, are non-invasive and, because urine is essentially free of cells, the potential problem of ex vivo production of mediators is minimised. In humans, LTE₄ is the stable bioconversion product of cysteinyl leukotriene metabolism in the lung,²⁷ and numerous studies²⁸⁻³² have now evaluated the metabolism, elimination, and pharmacodynamics of LTE₄ excretion into the urine.
following either intravenous infusion of LTC₄,²⁸²⁹ and LTE₄,³⁰ or inhalation of LTD₄.³¹⁻³² Overall, these studies have demonstrated the rapid excretion into urine of LTE₄ — either as an intact molecule or following enzymatic conversion from LTC₄ and LTD₄ — within four hours of either systemic administration or pulmonary inhalation. In the absence of either renal or hepatic dysfunction, measurement of urinary LTE₄ excretion may be used to assess endogenous whole body cysteinyl leukotriene production in vivo in man, and this has been utilised in numerous studies both in the laboratory and in clinical asthma.

**EVIDENCE OF CYSTEINYL LEUKOTRIENE RELEASE FOLLOWING INDIRECT CHALLENGE**

**Allergen challenge**

Activation of mast cells classically by IgE-dependent mechanisms results in release of inflammatory mediators such as histamine, prostaglandin D₂, and the cysteinyl leukotrienes, and it is the end organ response to these mediators that accounts for many of the features of the immediate bronchial response to inhaled allergen. Several studies have shown increased levels of urinary LTE₄ excretion during early allergen-invoked bronchoconstriction.³³⁻³⁸ These data complement those obtained from BAL analysis following segmental allergen challenge to the lung²⁶ and also following nasal allergen provocation.²⁷⁻²⁹ By contrast, comparable elevations in urinary LTE₄ excretion during later allergen-invoked bronchoconstrictor responses are equivocal and have proved more difficult to interpret despite the demonstration of these products locally in the lung.²⁵ It is not clear from these observations during later allergen-invoked bronchoconstriction whether de novo cysteinyl leukotriene synthesis and release is occurring from cells such as eosinophils recruited to the airway, or the end organ response is consequent upon prior liberation of cysteinyl leukotrienes from mast cells during the earlier stages of allergen-provoked bronchoconstriction. This issue has still not been unequivocally clarified, even with the demonstration of significant attenuation of late allergen-induced bronchoconstriction by potent cysteinyl leukotriene receptor antagonists,⁴¹ but is worthy of further critical analysis.

**Exercise and cold air challenge**

Exercise is a common stimulus of bronchoconstriction in asthmatic subjects, although the exact pathogenic sequence of events underlying its causation remains unclear. Several mechanisms have been proposed, including mast cell mediator release secondary to respiratory water loss, and hyperosmolar provocation and vascular phenomena provoking oedema formation within the airway wall. Data concerning the participation of inflammatory mediators, particularly cysteinyl leukotrienes, in either the maintenance or induction of the exercise-induced bronchoconstriction are conflicting. A number of studies have shown no increase in cysteinyl leukotriene concentrations in either plasma,⁴² BAL fluid,⁴³ or urine⁴⁴ following exercise challenge. Similarly, inhalation of cold air is not associated with increased urinary eicosanoid production (GW Taylor, unpublished data). By contrast, a study in children did show a modest increase in urinary LTE₄ excretion⁴⁵ and small but significant increases in cysteinyl leukotrienes have been demonstrated in BAL fluid after hyperventilation-induced bronchoconstriction.⁴⁶ However, the most compelling evidence for a role for the cysteinyl leukotrienes in exercise-induced asthma (and, indeed, the bronchoconstriction invoked by hyperventilation of cold dry air which is believed to share the same mechanism) are the numerous studies which have shown amelioration of airways limitation either by selective blockade of the 5-lipoxygenase enzyme⁴⁷ or by selective end organ receptor blockade.⁴⁸⁻⁵¹

**Platelet activating factor (PAF) challenge**

The role of the ether-linked alkylphospholipid platelet activating factor (PAF) in asthma has attracted much attention although its precise role in the pathogenesis of asthma is not clear. In common with other inflammatory mediators, PAF is capable of reproducing many of the functional and histological features seen in asthma both in vivo and in vitro, including microvascular leakage, bronchoconstriction, and inflammatory cell activation. Despite causing bronchoconstriction following inhalation in humans,⁵²⁻⁵⁴ PAF does not possess direct contractile effects on human airway smooth muscle strips in cell-free media in vitro,⁵⁵ suggesting that some of its function in vivo may be mediated indirectly through the release of secondary mediators. In support of this, the generation of leukotrienes in response to PAF has been described from a number of animal preparations and purified human cells in vitro. Some of the acute bronchoconstriction in response to inhaled PAF in human subjects may be mediated by cysteinyl leukotrienes.⁵⁶ Subsequent support for a direct contributory role for cysteinyl leukotrienes in the airway response to PAF in humans has been demonstrated by the marked inhibitory effect of selective cysteine leukotriene receptor antagonists, SKF 104353 and ICI 204 219 on PAF-invoked bronchoconstriction.⁵⁷⁻⁵⁸ Furthermore, an oral PAF antagonist, UK 74505, significantly attenuated PAF-invoked rises in urinary LTE₄ levels.⁵⁹

**Aspirin challenge**

Some subjects with asthma are intolerant of aspirin and other non-steroidal anti-inflammatory drugs, but the aetiology of this phenomenon remains unclear. One hypothesis is that inhibition of the cyclooxygenase enzyme provokes bronchoconstriction by the "shunting" of arachidonic acid towards metabolism by cellular lipoxygenases. In support of this, pretreatment of sensitised human bronchus in vitro with indomethacin generates increased LTC₄ following immunological challenge.⁶⁰
Cysteinyl leukotrienes function significantly in asthma,67-69 neither acute nor bronchodilator component evidence21 and for perbronchial allergen.63 Baseline observations of urinary LTE4 excretion have also provided some useful information. A recent study has reported increased excretion of LTE4 in overnight urine samples in patients with nocturnal asthma which correlated with the magnitude of the morning dip.64 By contrast, Westcott et al65 found no correlation between baseline measurements of FEV1 and urinary LTE4 levels, and others have found no difference in urinary LTE4 excretion between asthmatic and non-asthmatic subjects under basal unchallenged conditions.3345

**EVIDENCE OF CYSTEINYL LEUKOTRIENE RELEASE DURING DISEASE EXACERBATIONS**

Taylor et al63 initially observed increases in urinary LTE4 levels in 24 hour urine collections in patients admitted to hospital with acute severe asthma, although there was a substantial overlap of urinary LTE4 measurements into the normal range. Furthermore, whilst urinary LTE4 levels tended to decrease during disease remission, this did not reach statistical significance. Drazen et al66 further evaluated the role of cysteinyl leukotrienes in patients presenting with acute airways obstruction. Urinary LTE4 excretion was significantly higher in those patients classified as “responders” (determined on the basis of airway reversibility to a nebulised β2 agonist) compared with “non-responders” and normal volunteers. This provides strong support for a bronchoconstrictor role for cysteinyl leukotrienes in acute severe asthma, particularly in those patients in whom bronchoconstriction per se (and, by inference, heightenened bronchodilator responsiveness) is a major component of their airways obstruction.

**EVIDENCE FOR CYSTEINYL LEUKOTRIENE RELEASE UNDER BASAL CONDITIONS**

Recent evidence66-68 suggests that basal airway tone in asthmatic subjects is influenced by endogenous cysteinyl leukotrienes and may be responsible, at least in part, for persistent bronchoconstriction. For example, raised levels of cysteinyl leukotrienes have been demonstrated in BAL fluid before endobronchial allergen challenge in atopic asthmatic subjects compared with control groups.66 Further, the cysteinyl leukotriene receptor antagonists, ICI 204 219 and MK-571, and the hydroxamic acid 5-lipoxygenase inhibitor, zileuton, have shown significant acute bronchodepressor effects in asthmatics of moderate severity.66-68 Whilst these observations have been supported in preliminary, albeit prolonged, dosing studies in chronic asthma,67 neither MK-571 nor ICI 204 219 significantly improved pulmonary function prior to exercise challenge although this may have been a reflection of the mild airways obstruction in the population of patients studied.66-69 Baseline observations of urinary LTE4 excretion have also provided some useful information. A recent study has reported increased excretion of LTE4 in overnight urine samples in patients with nocturnal asthma which correlated with the magnitude of the morning dip.64 By contrast, Westcott et al65 found no correlation between baseline measurements of FEV1 and urinary LTE4 levels, and others have found no difference in urinary LTE4 excretion between asthmatic and non-asthmatic subjects under basal unchallenged conditions.3345

**Therapeutic intervention**

If cysteinyl leukotrienes play a significant part in the pathogenesis of asthma, then attempts to modulate their pharmacological actions should be of some therapeutic benefit. Clarification of the role of cysteinyl leukotrienes in asthma has to date focused on three therapeutic strategies: (1) dietary provision of alternative fatty acid substrates within membrane phospholipids thereby yielding products with less pro-inflammatory activity;67 this approach has been largely unsuccessful67 and will not be discussed further; (2) pharmacological inhibition of specific synthetic enzymes, particularly 5-lipoxygenase, and (3) modulation of end organ effects with selective cysteinyl leukotriene receptor antagonists. The remainder of this review will concentrate on these latter two approaches, with emphasis on the effect of these classes of drugs on indirect bronchoconstric tor challenges administered to the airway, and their effect in chronic persistent asthma itself, rather than a discussion of those studies in which antagonism of leukotrienes has been evaluated.

**5-LIPOOXYGENASE INHIBITION**

Early efforts to examine the efficacy of 5-lipoxygenase inhibitors failed to show any therapeutic benefit67-73 or evidence of adequate enzyme blockade. Zileuton (A-64077), an oral hydroxamic acid 5-lipoxygenase inhibitor,76 has proved more encouraging. Following nasal allergen challenge, symptoms of nasal congestion and LTβ concentrations in nasal lavage fluid were significantly reduced although cysteinyl leukotriene concentrations were not evaluated.76 In a separate study zileuton significantly ameliorated the bronchoconstriction invoked by cold dry air.77 In contrast, when administered three hours before inhaled allergen challenge, zileuton did not significantly attenuate either early or late allergen-invoked bronchoconstriction or the allergen-invoked airway hyperresponsiveness.77 Although urinary LTE4 excretion was reduced by almost 50%, the lack of clinical effect in the airway may have been related to insufficient inhibition of 5-lipoxygenase.77 However, zileuton has shown significant acute bronchodilator effects in moderately severe asthmatic patients and in preliminary chronic dosing studies.76 A further therapeutic target has been to antagonise the regulatory protein 5-lipoxygenase activating...
protein (FLAP), since expression of both 5-lipoxygenase and FLAP are necessary for cellular leukotriene synthesis. To date only one FLAP antagonist, MK-886, has progressed to clinical trials in laboratory-provoked airways obstruction. Whilst demonstrating marked attenuation of both early and late allergen-invoked bronchoconstriction and urinary LTE4 excretion, no effect was seen on the allergen-invoked increase in airways responsiveness although this may have been a reflection of the study design.

Cysteinyl leukotriene receptor antagonism
As with the early 5-lipoxygenase inhibitors, initial studies with cysteinyl leukotriene antagonists (L-649 923, LY-171 883, and L-648 051) administered orally or by inhalation in standard allergen provocations were disappointing. The development of more potent and selective second generation cysteinyl leukotriene receptor antagonists (MK-571, ICI 204 219, SK&F 104 353, RG12525) administered either by inhalation, oral or intravenous routes have proved more encouraging both in laboratory-provoked airway narrowing and in clinical asthma itself. Numerous recent studies have demonstrated their inhibitory effect against aspirin, PAF, and allergen, and (despite the contradictory evidence from direct mediator measurements), exercise challenge. For example, Manning et al. using the highly potent and selective intravenous LTD4 receptor antagonist, MK-571, showed significant attenuation of both the magnitude and duration of exercise-induced bronchoconstriction, suggesting an important role for LTD4 in this condition. A similar observation has been reported with the equally potent LTD4 receptor antagonist ICI 204 219 when administered orally before exercise challenge. Furthermore, despite its modest effect following allergen-induced bronchoconstriction, LY 171 883 reduced the bronchospastic response to hyperventilation of isoacpinic cold air, suggesting that cysteinyl leukotrienes are involved in this response. Administration of an oral dose of ICI 204 219 two hours before allergen challenge significantly attenuated both allergen-induced early and late bronchoconstrictor responses and the allergen-invoked increase in airways reactivity. A subsequent study with an inhaled preparation of the same drug inhibited only the early bronchoconstriction following allergen administration; the discrepancy in effects of the different routes of administration were thought to reflect different pharmacokinetic and pharmacodynamic profiles. Two further studies of different design have shown that, following ingestion of ICI 204 219, increased doses of allergen were required to provoke comparable bronchoconstriction to those observed on the placebo limb. Finally, intravenous administration of MK-571 resulted in a dose-related inhibition of allergen-induced bronchoconstriction, and inhalation of SK&F 104 353 significantly inhibited the bronchoconstriction invoked by PAF, exercise, and aspirin in susceptible subjects.

As previously discussed, cysteinyl leukotrienes may contribute to resting bronchodilator tone in asthmatic subjects. Both ICI 204 219 and MK-571 have acute bronchodilator actions additive to those of inhaled salbutamol in patients with moderately severe asthma. By contrast, in subjects requiring only occasional use of β2 agonist bronchodilators and in whom the airways limitation is minimal, these drugs appear to have little effect on basal airway tone.

Effects of cysteinyl leukotriene antagonists in chronic asthma have also been reported. Dosing with LY 171 883 for six weeks resulted in a modest rise in airway calibre which was associated (in a subpopulation of patients) with a significant reduction in β2 agonist usage. Similar data with more potent receptor antagonists (ICI 204 219, MK-571, and MK-12525), administered for up to six weeks, have also shown an improvement in airway physiology and symptom scores in patients with asthma.

Conclusions
The clinical entity of asthma is now known to comprise a combination of separate but intimately related pathophysiological processes including variable airways obstruction, bronchial hyperresponsiveness, and inflammation of the airways. The initiation and propagation of inflammation of the airways results from the coordinated collaboration of numerous inflammatory cells (resident in, or recruited to, the airway) and their cellular products. Whilst many would agree that no single inflammatory mediator is responsible for all the clinical and pathological events in bronchial asthma, there is now substantial evidence that the cysteinyl leukotrienes play an important part in the pathophysiology of the disease. Not only are they capable of reproducing many of the functional and histological features of asthma, there is now abundant literature on their release, both in acute severe asthma and following laboratory-provoked bronchoconstrictor challenges, and on their contribution to the resting bronchodilator tone in asthmatic patients.

Even when analytical approaches can be trusted to generate good quality data, it is important to interpret data correctly, particularly when invoking mechanistic roles for cysteinyl leukotrienes in mediating indirect bronchoconstriction. Such interpretation of mechanistic events in vivo is important, given that apparently conflicting evidence may arise from either pharmacological modulation of a physiological response when compared with direct mediator measurements in biological matrices (such as plasma, urine or alveolar lavage) during the response. The translation from identification of a putative mechanism to a useful therapeutic role is often not conclusive and further corroborative evidence should, if possible, be sought.

Present therapeutic strategies in asthma have two aims: (1) attenuation of airways in-
flammmation, and (2) promotion of broncho-
dilation.\textsuperscript{41} In this context it seems apposite to examine the capabilities of pharmacological agents which potently inhibit cysteiny leuko-
triene synthesis or selectively antagonise their end organ effects and to determine how these may be disease modifying in asthma. The Brit-
ish Thoracic Society recently updated their guidelines for the management of both acute severe and chronic persistent asthma\textsuperscript{2} in which they advocate the use of inhaled glucocorticoids as first line anti-inflammatory therapy for all but the mildest of asthmatic patients. Further,
of the currently available bronchodilators in clinical use, selective β\textsubscript{2} adrenergic agonists are by far the most effective. It is therefore against these therapies that mediator antagonists or synthesis inhibitors must be evaluated. Whilst 5-lipoxygenase inhibitors and cysteiny leukotriene antagonists have demonstrable protective effects against many broncho-
provocative insults and can promote broncho-
dilation, it is clear that further clinical studies are required before they can be added to, or replace, existing therapy for asthma. To date, there have been few clinical studies evaluating the putative anti-inflammatory properties of these drugs, in contrast to the many clinical and histological studies with glucocorticoids in asthmatic patients across a wide spectrum of disease severity.\textsuperscript{42} Furthermore, whether 5-lipo-
oxigenase inhibitors and cysteiny leukotriene receptor antagonists will induce changes of sufficient magnitude in airways reactivity to be considered disease modifying still remains unanswered. Nevertheless, if further studies in chronic persistent asthma confirm the current promising evidence, then agents which pharmacologically modulate the in vivo actions of cysteiny leukotrienes should provide an ad-
ditional therapeutic approach for the treatment of asthma.

This paper was commissioned and funded by Zeneca Phar-
maceuticals Ltd.

1 Samuelson B. Leukotrienes: mediators of immediate hyper-
responsiveness reactions and inflammation. Science 1983;
5 Piccenni GL, Kallner MA. The potential roles of leuko-
trienes in bronchial asthma. Am Rev Respir Dis 1991;143:
7 Dahlen SE, Hammarstrom G, Hedquist P, Björck T, Granström E, Dahlen B. Allergen challenge of lung tissue from asth-
maics elicits bronchial contraction that correlated with the release of leukotrienes C\textsubscript{4}, D\textsubscript{4}, and E\textsubscript{4}, Proc Natl Acad Sci USA 1984;81:1712-6.\textsuperscript{43}
10 Dahlen S-E. Leukotrienes as mediators of airway ob-
struction and bronchial hyperresponsiveness. In: Barnes PJ, Bjerre P, Walmrath DA, editors. Asthma: basic mech-
anisms and clinical management. Oxford: Blackwells, 1988:
10-205.
1009.


